30 Minutes to Relief? Real-World Data Say Yes
Real-world patient-reported outcomes show high responder rates, favorable tolerability, and consistent satisfaction with hyoscine butylbromide plus for menstrual pain self-treatment.
By
Kathryn Wighton
January 9, 2026
Clinical Scorecard: 30 Minutes to Relief? Real-World Data Say Yes
At a Glance
Category Detail
Condition Dysmenorrhea Key Mechanisms Hyoscine butylbromide (HBB) and paracetamol combination for pain relief. Target Population Adult women experiencing menstrual pain. Care Setting Noninterventional study conducted via an online patient platform.
Key Highlights
Median time to meaningful pain relief was 38 minutes. 91% of patients achieved a clinically meaningful response within 4 hours. Pain intensity decreased significantly at all postdose assessments. 96% of patients reported at least one dysmenorrhea symptom at baseline, reduced to 70% at 4 hours. Over 90% of patients were satisfied or very satisfied with treatment effectiveness. Guideline-Based Recommendations
Diagnosis
Assess menstrual pain severity using numeric rating scale (NRS). Management
Consider HBB 10 mg and paracetamol 500 mg for self-treatment of dysmenorrhea. Monitoring & Follow-up
Monitor pain intensity and symptom reduction at multiple time points post-treatment. Risks
Be aware of potential nonserious treatment-emergent adverse events. Patient & Prescribing Data
Women aged around 34 years with moderate to severe menstrual pain.
Patients typically used 1 to 2 tablets per day over a median of 3 days during menstruation.
Clinical Best Practices
Encourage patients to report pain intensity using NRS. Educate patients on the safe use of HBB and paracetamol combination. Consider patient satisfaction as a key outcome measure. References
